The next generation sequencing market offers significant opportunities by enhancing the diagnosis and treatment of chronic ...

DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, today unveils a new Early Access Program, offering clinical ...

Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

With the MiSeq™ i100 Series, Illumina continues to set the highest standards.Advancements in system design, sequencing chemistry, and data analysis deliverthe simplest, fastest benchtop sequencing and ...

DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, ...

Ipseity Diagnostics partners with Vignan University to enhance molecular research and diagnostic solutions in Andhra Pradesh.

The Vietnam Academy of Science and Technology (VAST) organized a ceremony in Hanoi on December 11 to announce DNA ...

Recent advances in the treatment of non-small cell lung cancer (NSCLC) have led to improved patient outcomes, particularly ...

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after ...

Zurletrectinib has been included in the “SPARK Program” by China’s National Medical Products Administration (NMPA), a pilot initiative to encourage the development of pediatric anti-tumor drugs.

Accelerated sequencing technologies, AI-enabled analytics, newborn screening expansion, and government-backed genomic initiatives fuel rapid growth across North America, Europe, and ...

Pillar Biosciences announced today an expansion of its existing laboratory access program with AstraZeneca for NGS-based ...